Barinthus Biotherapeutics

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company based in the United Kingdom. It specializes in developing novel immunotherapies aimed at guiding T cells to combat autoimmunity, inflammatory diseases, infectious diseases, and cancer. The company is publicly traded on the Nasdaq under the ticker symbol BRNS. Formed in 2021 from the merger of Vaccitech plc and Avidea Technologies, Barinthus Biotherapeutics builds on a strong foundation in immunotherapy development. The company utilizes advanced platforms, including Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), to induce immune responses against various diseases. Its SNAP Synthetic Platforms focus on tolerance and cancer immunotherapy. Barinthus targets conditions such as hepatitis B, HPV, prostate cancer, and autoimmune diseases. With a dedicated team of over 100 professionals, Barinthus Biotherapeutics is committed to advancing its immunotherapy pipeline. The company has garnered support from notable investors and partners, enhancing its mission to improve patient outcomes through innovative treatments.